相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
33.3%
招募中
4
66.7%
暂无批准数据
- A Kookmin University-led team integrated genomic, transcriptomic, epigenomic, proteomic, and phosphoproteomic data from over 100 medulloblastoma patients to refine the conventional four molecular groups into seven distinct subtypes. - The SHHβ and G4γ subtypes showed enhanced neuronal differentiation and relatively favorable outcomes, while SHHα, G4α, and G4β were linked to higher risk of recurrence and progression. - Researchers identified subtype-specific protein signaling pathways and potential therapeutic targets, laying groundwork for precision medicine-based targeted therapies. - The findings, published in Experimental & Molecular Medicine, address the poor survival rates after medulloblastoma recurrence and the need for molecularly guided treatment.
- HKSH Medical Group and Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen signed a memorandum of understanding on December 11, 2025, to advance precision proton therapy capabilities in the Greater Bay Area. - The collaboration aims to enhance clinical applications of proton therapy, specialist training, and cancer management research as part of China's "Healthy China 2030" initiative to improve cancer patient survival rates. - HKSH operates the first and only proton therapy center in Hong Kong and the Greater Bay Area, positioning it as a vital reference for national proton therapy advancement. - The partnership will facilitate integration of healthcare management, talent development, research innovation, and technical exchange to deliver international-standard precision medical services across both regions.
- The phase 3 FZOCUS-1 trial demonstrated that fuzuloparib monotherapy significantly improved progression-free survival compared to placebo in patients with newly diagnosed advanced ovarian cancer. - Adding apatinib to fuzuloparib did not provide additional benefit over fuzuloparib alone, marking the first study to show that combining an antiangiogenic agent with a PARP inhibitor does not improve outcomes in BRCA-mutated or HRD-positive ovarian cancer. - Fuzuloparib monotherapy achieved a median PFS of 29.9 months versus 11.1 months with placebo, representing a 42% reduction in disease progression risk. - The safety profile was consistent with previous PARP inhibitor studies, with hematological toxicities being the most common grade 3 or higher adverse events.
- MedPacto's Vactosertib demonstrated a 36.4% objective response rate in Phase 1 osteosarcoma trials, including one complete remission case, representing more than three times the efficacy of existing treatments. - The company has expanded its Phase 2 clinical trial to six major Korean hospitals and received compassionate use requests from prominent US medical institutions including Johns Hopkins and Stanford. - Vactosertib has received orphan drug designation in the US and Europe, along with FDA Fast Track designation, with Breakthrough Therapy designation discussions ongoing.
- Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021. - Korea University will conduct the first large-scale plasma proteomics study of its kind, analyzing 20,000 samples from cancer patients and healthy controls to develop AI-driven diagnostics for early-onset cancers in young adults. - The three-year study, funded by Korea's K-Health MIRAE initiative, aims to identify novel blood-based biomarkers for cancer detection in patients in their 20s and 30s using samples from leading Korean cancer institutions. - The new workflow identifies up to 10 times more proteins than conventional mass spectrometry methods and completes 80-sample batches in under 5 hours of automated runtime.
- Phase 1/2 study data presented at the 2025 AACR Annual Meeting revealed promising efficacy of fruquintinib plus capecitabine as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer patients. - At a median follow-up of 5.7 months, the disease control rate reached 90.9% with median progression-free survival not yet reached, and two patients experienced disease control lasting more than 430 days. - The recommended phase 2 dose was established at 5 mg daily of fruquintinib on days 1-14 of each 3-week cycle, with a manageable safety profile showing 87.5% of patients experiencing treatment-related adverse effects, mostly mild to moderate.
- Toripalimab induction therapy plus chemotherapy significantly improved progression-free survival compared to chemotherapy alone in patients with bulky, unresectable stage III non-small cell lung cancer, with 1-year PFS rates of 85.6% versus 54.5%. - The treatment reduced the risk of disease progression or death by 74% (HR 0.26, P=0.012) and achieved a significantly higher objective response rate of 77.8% compared to 40.0% with chemotherapy alone. - The combination demonstrated manageable toxicity with no grade 4 or 5 pneumonitis events, while grade 1/2 pneumonitis occurred in 37% of toripalimab patients versus 48% in the chemotherapy-only group. - Results from the randomized phase 2 InTRist study support advancing to phase 3 trials for this promising treatment strategy in high-risk lung cancer patients.
- Combination therapy with Afinitor and Somatuline demonstrates a significant improvement in progression-free survival (PFS) compared to Afinitor alone in patients with unresectable or recurrent GEP-NETs. - The phase 3 STARTER-NET trial reported a median PFS of 29.7 months in the Afinitor plus Somatuline group versus 11.5 months in the Afinitor monotherapy group. - The combination therapy showed an acceptable safety profile, with manageable side effects, positioning it as a potential new first-line treatment for GEP-NETs. - Subgroup analysis indicates that patients with a Ki-67 score above 10%, indicating more aggressive tumors, may particularly benefit from the Afinitor and Somatuline combination.
- The combination of everolimus and lanreotide significantly prolonged progression-free survival (PFS) compared to everolimus alone in GEP-NETs. - Median PFS reached 29.7 months in the combination arm versus 11.5 months in the everolimus monotherapy arm, demonstrating a substantial improvement. - The objective response rate was significantly higher in the combination group (23.0%) compared to the everolimus group (8.3%). - The combination therapy showed a manageable safety profile, suggesting its potential as a new first-line treatment option.
• Disitamab vedotin (RC48) demonstrates an objective response rate of 34.4% in HER2-expressing metastatic breast cancer patients with abnormal PAM pathway activation. • The disease control rate with disitamab vedotin was 81.97% across all HER2-expressing metastatic breast cancer patients in the phase 2 trial. • Median progression-free survival was 3.5 months in all patients, with no significant difference between HER2-positive and HER2-low subgroups. • The safety profile of disitamab vedotin was manageable, with most adverse events being grade 1 or 2, and no treatment-related deaths reported.
